Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved an extension of marketing ...

Day 0 was the day a dog received its first dose. For dogs randomised to bedinvetmab, the UK dosage chart (Supplementary material) ensured a bedinvetmab dosage of 0.5 to 1.0 mg/kg using a ready-to-use ...

Head-to-head comparison data versus osimertinib showed Rybrevant plus Lazcluze significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell ...

Johnson & Johnson’s (J&J’s) Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by one year above the standard of care ...

Head-to-head comparison data versus osimertinib showed RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly extended OS in the first-line treatment of patients with locally ...

The phase 3 MARIPOSA study has been evaluating Rybrevant (amivantamab), an EGFR-MET bispecific antibody, plus Lazcluze (lazertinib), a third-generation EGFR tyrosine kinase inhibitor (TKI), against ...

RARITAN, N.J. - Johnson & Johnson (NYSE:JNJ) disclosed results from its Phase 3 MARIPOSA study, indicating that RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib) significantly ...

Rash leading to dose reduction occurred in 5% of patients, and RYBREVANT ® was permanently discontinued due to rash in 0.7% of patients. Toxic epidermal necrolysis occurred in one patient (0.3% ...

RARITAN, N.J. - Johnson & Johnson (NYSE:JNJ) disclosed results from its Phase 3 MARIPOSA study, indicating that RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib ...

In CHRYSALIS, rash occurred in 74% of patients treated with RYBREVANT ® as a single agent, including Grade 3 rash in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 ...

Rybrevant plus Lazcluze extended overall survival beyond three years in first-line EGFR-mutated NSCLC, surpassing osimertinib’s 36.7 months. 56% of patients on Rybrevant plus Lazcluze were alive ...